ClinicalTrials.gov
ClinicalTrials.gov Menu

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00307177
Recruitment Status : Completed
First Posted : March 27, 2006
Last Update Posted : December 5, 2014
Sponsor:
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)

March 24, 2006
March 27, 2006
December 5, 2014
August 2004
April 2005   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00307177 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma
Evaluation of the Reactogenicity and Immunogenicity of Different Doses of Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma: A Phase II, Double-Blind Pilot Study
The purpose of this research is to compare reactions and antibody responses following receipt of different doses of the experimental influenza vaccine or standard influenza vaccine.
Influenza is a common respiratory infection caused by viruses. Epidemics of influenza occur each winter and are responsible for more than 20,000 deaths each year in the United States. Most of these deaths occur among elderly persons and among people of all ages who suffer from a chronic disease. Standard influenza vaccines may not be as effective at protecting cancer patients as the general population from getting influenza. This research study will test an experimental influenza vaccine consisting of the important flu virus protein that stimulates protection. It is produced by genetic techniques in cultured cells and allows higher doses of the protein to be used. Influenza vaccines made this way have been given to humans in the past and the vaccine was well tolerated. It is expected that higher doses of this vaccine can be given with minimal reactions, as well as whether such a vaccine stimulates higher levels of infection-fighting proteins (or antibodies) in the blood than standard doses of the licensed influenza vaccine. This study will evaluate the reactogenicity and immunogenicity of a recombiant influenza vaccine in non-Hodgkin's B cell lymphoma.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Influenza
  • Biological: Trivalent inactivated influenza vaccine
    Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
  • Biological: Trivalent Baculovirus-expressed Influenza HA vaccine
    Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
  • Experimental: Arm D
    25 subjects receive Recombinant rHA0 vaccine at 135 mcg per rHA0, via IM injection on Day 0
    Intervention: Biological: Trivalent Baculovirus-expressed Influenza HA vaccine
  • Experimental: Arm C
    25 subjects receive Recombinant rHA0 vaccine at 45 mcg per rHA0, via IM injection on Day 0
    Intervention: Biological: Trivalent Baculovirus-expressed Influenza HA vaccine
  • Experimental: Arm B
    25 subjects receive Recombinant rHA0 vaccine at 15 mcg per rHA0, via IM injection on Day 0
    Intervention: Biological: Trivalent Baculovirus-expressed Influenza HA vaccine
  • Active Comparator: Arm A
    25 subjects receive Standard TIV at 15 mcg HA per virus, in a total volume of 0.5 mL, by deep intramuscular (IM) injection on Day 0
    Intervention: Biological: Trivalent inactivated influenza vaccine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
28
100
April 2005
April 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with non-Hodgkin's B-cell lymphoma (NHL) including follicular, large cell and Mantle cell lymphoma will be included.
  • Patients in complete clinical remission and determined to have no evidence of active disease (NED).
  • Ambulatory, medically stable persons; community dwelling; able to give informed consent and available for all study visits; able to understand and comply with planned study procedures; ECOG performance status less than or equal to 2.
  • Medically stable subjects may have underlying illnesses such as hypertension, diabetes, ischemic heart disease, or hypothyroidism, but their symptoms/signs are controlled with medical therapy.
  • Patients with a non-metastatic secondary solid tumor or malignancies not currently (< 3 months) being treated will be included.
  • Patients greater than or equal to 18 years of age who have given informed consent and signed the IRB approved informed consent.

Exclusion Criteria:

  • Patients with Hodgkin's disease, and T-cell lymphoma.
  • Patients undergoing antineoplastic therapy.
  • Patients who have received chemotherapy within the past 3 months.
  • Individuals who were given rituximab (ibritumomab tiuxetan) in < 6 months.
  • Patients receiving systemic corticosteroids and/or high-dose inhaled steroids (>800 mcg per day of beclomethasone dipropionate or equivalent).
  • Splenectomized individuals will not be included.
  • Known allergy to eggs or other components of vaccine (e.g., thimerosal).
  • Acute or chronic condition that (in the opinion of the investigator) would render vaccination unsafe or would interfere with the evaluation of responses (including but not limited to the following: acute febrile illness, known chronic liver disease; significant renal disease; oxygen-dependent chronic lung disease, New York Heart Association Functional Class III or IV dyspnea; unstable or progressive neurologic disorder; insulin-dependent diabetes mellitus).
  • Concomitant use of investigational vaccines and/or other medications within 4 weeks prior to study entry, or expected use of experimental or licensed vaccines or blood/blood products prior to study completion.
  • Previous exposure to parenteral immunoglobulins or other blood product within 6 months prior to enrollment into the study.
  • Subject is enrolled in a conflicting clinical trial.
  • Use of experimental vaccines or medications within one month of study entry.
  • Any acute or chronic condition which in the opinion of the investigator would render vaccination unsafe or interfere with the evaluation of response.
  • Patients with a known history or risk factors (IV drug abuse or casual sex within the past year) of Hepatitis B, Hepatitis C, or Human Immunodeficeincy Virus.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00307177
04-036
Not Provided
Not Provided
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
November 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP